A5084835585- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Prostate Cancer Treatment and Research
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Single-cell and spatial transcriptomics
- Protein Degradation and Inhibitors
- Microfluidic and Bio-sensing Technologies
- Sirtuins and Resveratrol in Medicine
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Ubiquitin and proteasome pathways
- Microfluidic and Capillary Electrophoresis Applications
- Biosensors and Analytical Detection
- Microtubule and mitosis dynamics
- 3D Printing in Biomedical Research
- Cancer, Hypoxia, and Metabolism
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Renal and related cancers
- Immune Cell Function and Interaction
- Advanced Biosensing Techniques and Applications
- Innovative Microfluidic and Catalytic Techniques Innovation
University of Wisconsin–Madison
2016-2025
University of Wisconsin Carbone Cancer Center
2016-2025
University of Wisconsin System
2024
Madison Group (United States)
2018
Subunits of the chromatin remodeler SWI/SNF are most frequently disrupted genes in cancer. However, how post-translational modifications (PTM) subunits elicit epigenetic dysfunction remains unknown. Arginine-methylation BAF155 by coactivator-associated arginine methyltransferase 1 (CARM1) promotes triple-negative breast cancer (TNBC) metastasis. Herein, we discovered dual roles methylated-BAF155 (me-BAF155) promoting tumor metastasis: activation super-enhancer-addicted oncogenes recruiting...
Background Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances the identification circulating tumor cells (CTCs) may be a less method to assay for these purposes. These liquid biopsies rely on accurate CTCs from diverse populations blood, where some share characteristics with normal blood cells. While many can excluded by their high expression CD45, neutrophils and other immature...
Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important context immunotherapies, which target key immune-tumor interactions. Unlike tissue biopsies, serial real-time profiling mRCC feasible with our noninvasive circulating tumor (CTC) approach.We collected 457 longitudinal liquid from 104 patients enrolled one two studies, either prospective cohort or phase II...
BackgroundNeuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes prognosis and management metastatic cancer.MethodsWe performed analytical validation a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify limit quantification (LOQ) in cell lines, synthetic cDNA, patient samples. We next profiled 116 longitudinal samples from prospectively collected institutional cohort 17 patients with (7 NEPC, 10 adenocarcinoma) as well 265 139 enrolled 3...
Abstract The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution transitions in has been limited challenges collecting serial tissue biopsies on treatment, which can be overcome using blood-based liquid biopsies. Utilizing a novel circulating tumor cell (CTC) isolation approach, we collected 273 CTC samples from 117 cancer RNA sequencing. 146 70 had purity...
Abstract Background: Liquid biopsies in advanced solid tumors can provide a unique noninvasive approach to monitor disease burden over time. Detection and capturing circulating tumor cells (CTCs) melanoma patients have faced many challenges limitations. In our study, we use novel, high-sensitivity, CTC technology assess numerical heterogeneity of serially collected CTCs stage undergoing systemic treatment correlate dynamics with response risk progression. Methods: We utilize microfluidic...
The concept of high liquid repellency in multi-liquid-phase systems (e.g., aqueous droplets an oil background) has been applied to areas biomedical research realize intrinsic advantages not available single-liquid-phase systems. Such have included minimizing analyte loss, facile manipulation single-cell samples, elimination biofouling, and ease use regarding loading retrieving the sample. In this paper, we present generalized design rules for predicting wettability solid-liquid-liquid...
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available patient stratification or evaluation of therapy resistance. Given dynamic and heterogeneous nature clear RCC (ccRCC), tumor biopsies provide limited clinical utility, but liquid could overcome these limitations. Prior biopsy approaches lacked clinically relevant detection rates ccRCC. This study employed ccRCC-specific markers, CAIX CAXII, to...
Magnetic bead-based analyte capture has emerged as a ubiquitous method in cell isolation, enabling the highly specific of target populations through simple magnetic manipulation. To date, no "one-size fits all" bead been widely adopted leading to an overwhelming number commercial beads. Ultimately, ideal is one that not only facilitates isolation but also proves compatible with widest range downstream applications and analytic endpoints. Despite diverse offering sizes, coatings, conjugation...
Automated magnetic bead sample preparation platform for positive/negative cell selection and molecular endpoints.
Centrosome amplification (CA) is a common phenomenon in cancer, promotes genomic stability and cancer evolution, has been reported to promote metastasis. CA stochastic gain/loss of chromosomes during cell division, known as chromosomal instability (CIN). However, it unclear whether present circulating tumor cells (CTCs), the seeds for Here, we surveyed CTCs from human subjects with metastatic breast cancer. were captured by CD45 exclusion selection EpCAM‐positive using an exclusion‐based...
199 Background: The detection of genomic alterations in cancer is critical for identifying clinically actionable treatment decisions. Tumor samples historically have been required, but obtaining tissue molecular profiling not always feasible, especially the metastatic setting. isolation and analysis cell-free DNA (cfDNA) including circulating tumor (ctDNA) via blood-based “liquid” biopsies offers non-invasive sampling tumor. Recently, fragmentation patterns cfDNA (i.e. “fragmentomics”)...
// Mikolaj Filon 1 , Bing Yang Tanaya A. Purohit Jennifer Schehr 2 Anupama Singh Marcelo Bigarella Peter Lewis 3 John Denu Joshua Lang 4 and David F. Jarrard Department of Urology, School Medicine Public Health, University Wisconsin, Madison, WI 53705, USA Hematology/Oncology, Biomolecular Chemistry, Carbone Comprehensive Cancer Center, Correspondence to: Jarrard, email: jarrard@urology.wisc.edu Keywords: prostate cancer; circulating tumor cells; p300/CBP Received: May 16, 2023 Accepted:...
PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components including HLA I expression. downregulation may contribute resistance, warranting its evaluation attempts guide patient selection. In addition, earlier detection of acquired resistance could prompt change treatment prolong survival. Analysis circulating cells (CTCs)...
Invariant natural killer T (iNKT) cells are a conserved population of innate lymphocytes that uniquely suitable as off-the-shelf cellular immunotherapies due to their lack alloreactivity. Two major subpopulations human iNKT have been delineated, CD4
225 Background: ctDNA monitoring has shown promising results in predicting relapse resected solid tumors. Its role treatment response assessment and survival outcomes the unresectable or metastatic disease setting merits further investigation. In our study, we attempt to assess of early changes response, progression, overall pts with advanced stage melanoma/skin cancer treated ICI therapy. Methods: A retrospective analysis using a personalized, tumor-informed assay (Natera) on prospectively...
Abstract iNKT cells are innate-like CD1d-restricted T that mediate potent anti-tumor responses in murine models and have shown therapeutic potential clinical trials. In humans, expression of CD4 delineates two functionally distinct cell subsets, with CD4- mainly producing TH1 cytokines showing cytolytic activity, while CD4+ display a polyfunctional phenotype linked to regulatory pathways. Here, we used an EBV-driven B-lymphoma model investigate the effects these subsets. live imaging system,...
Abstract Introduction: Androgen receptor pathway inhibitors (ARPIs) have been shown to improve survival for men with metastatic prostate cancer, however, the use of 2nd line ARPIs has limited efficacy. There is a critical need develop biomarker-driven treatment strategies this clinical need. We previously reported on novel circulating tumor cell (CTC) multiplexed mRNA biomarker that prognostic and predictive capability in utility trials detect AR- driven resistance Neuroendocrine Prostate...
547 Background: Despite recent therapeutic advancements for patients with mUC, including checkpoint inhibitors (CPIs), anti-FGFR and antibody-drug conjugates (ADCs), biomarker data to predict response identify mechanisms of resistance remain limited. Ongoing randomized clinical trials evaluating the combination CPIs ADCs in these pts underscore need develop biomarkers better understand who might best respond therapies. Here, we employ a liquid biopsy approach molecularly characterize...
247 Background: The mainstay of therapy in metastatic prostate cancer is androgen receptor (AR) signaling inhibition. However, the emergence early castration resistance or neuroendocrine transformation associated with poor prognosis. Reliable biomarkers are needed to identify these patients and guide selection clinical therapy. Methods: mRNA was isolated from EpCAM-positive circulating tumor cells (CTCs) CSPC, CRPC, NEPC measure expression KLK2, KLK3 (PSA), TMPRSS2, FOLH1 (PSMA),...
Abstract Background: Histone modifying enzymes (HMEs) hold significant promise as targets for drug discovery in cancer. acetyltransferases (HATs) and histone deacetylases (HDACs) dictate the presence of acetyl marks, which regulate openness chromatin transcriptional activation. We previously developed a novel array on chip to measure HME dysregulation with development castration resistance (ACS Chem Biol 2017). This approach identified decreased SIRT2 expression increased p300 activity leads...